Q3 Earnings Reports Show Slower Growth, But Plenty of Momentum Alongside Reform Proposals

Spread the love

<![CDATA[

In the third quarter of 2021, major U.S. cannabis multi-state operators (MSO) and several top Canadian licensed producers (LP) enjoyed healthy revenue and continued expansion. 

Cannabis Business Times and Cannabis Dispensary reviewed quarterly earnings statements and talked to industry executives to analyze how things went in the 2021’s penultimate quarter while preparing for another landmark year in 2022.

Growth Rates Settling In

While cannabis sales are still growing at a healthy clip overall, signs of a maturing market are starting to emerge: many U.S. companies saw a drop in revenue growth compared to earlier quarters. Illinois-based Green Thumb Industries (GTI) pulled in $233.7 million for the quarter, an increase of 5.3% on Q2 – quite a bit lower than its 14.1% increase from Q1 to Q2. Curaleaf, another major American MSO headquartered in Massachusetts, saw sequential growth drop 10x in Q3 compared to Q2. Cresco Labs, a top American cannabis wholesaler, reported 2.6% quarter-over-quarter growth compared to almost 18% in Q2.

In Canada’s smaller and more mature market the problem appeared to be worse. The Ontario giant Canopy Growth reported a 3.5% decline in net revenue compared to Q1 2022 (the Canadian equivalent to the U.S. Q2 2021). Aurora, another major Canadian cannabis player, experienced an 11% year-over-year decline in revenue for the quarter.

It’s true that some of these slowdowns are simply the result of seasonal shifts. It’s also possible that last year’s sales figures were inflated by widespread lockdowns due to the COVID-19 pandemic, a trend that has since eased.

“We saw some growth pulled forward in Q2 due to seasonality, stimulus spending and lifted COVID restrictions,” said Charlie Bachtell, CEO and co-founder of Cresco Labs, via email. “But if you look at the longer trendline, you see 40%-plus growth year-over-year across the industry.”

Long-term industry growth in the U.S. remains torrid – earlier this year, an updated projection by New Frontier Data predicted the market would bring in $43 billion in total revenue by 2025, an increase of 24% from 2020 sales numbers. Smaller firms in particular are still finding plenty of room for growth.

“Over the last two quarters we’ve experienced 220% year-over-year growth in the second quarter, and 117% growth in the third quarter,” said Michael Perlman, EVP of Investor Relations and Treasury at Jushi, who spoke to Cannabis Business Times and Cannabis Dispensary in a phone interview. Jushi, a retail-driven cannabis company based in Florida that’s grown rapidly the last few years, reported $54 million in revenue for the third quarter of 2021 – a 1500% increase from the same period just two years ago.

Legislation on the Horizon

Major states like Virginia and New York continue to pass laws that expand the country’s medical and adult-use sectors. However, many believe federal reform is necessary for the cannabis market to fulfill its potential.

Since Democrats won control of the House, Senate and White House in 2020, many in the industry have been optimistic about legislative reform. So far, that optimism remains unrewarded, but there are still two major opportunities to pass impactful cannabis laws.

The first is the States Reform Act (SRA), an unexpected proposal in the House from an even more unexpected source: South Carolina Republican Nancy Mace, a first-year congresswoman representing the east coast of her state. The SRA, which would allow states to set up their own systems to regulate cannabis and levy a 3% federal tax, has drawn mixed feedback from the industry.

The other is the National Defense Authorization Act (NDAA), which sets the annual budget for the U.S. military. The House passed a version of the NDAA with cannabis banking protections similar to the Secure and Fair Enforcement (SAFE) Banking Act. The bill still needs to be approved by the Senate – something unlikely to happen until December – where the provisions could be removed. If passed and signed into law, banking reform alone would be a significant step for the industry.

“More affordable access to capital, the ability to use credit cards, normalized banking…these are essential steps for an equitable industry,” added Bachtell.

Perlman agreed, saying he believes banking protections will benefit the industry as a whole by providing companies of all sizes with access to traditional services like business loans.

“SAFE Banking won’t only positively impact the larger companies in the industry,” he said. “We [larger cannabis corporations] have access to capital – it’s the smaller guys, the social equity operators, that are not going to have access to capital. … [Without banking access] they’re ultimately going to sell and flip these licenses to the more well-capitalized guys.”

But advocates for change in the industry know that legislative potential doesn’t mean much until it’s realized. Including its most recent passing of the NDAA, the House has passed the SAFE Banking Act five times since 2019.

Looking to 2022

Regardless of federal movement, 2022 is set to be another big year for cannabis. Major states like Connecticut and New Jersey are projected to begin adult-use sales. New York was also set to start sales in 2022 but recently announced a delay to licensing until 2023. These three states alone represent a potential cannabis market of over $5 billion. 

A few other prominent states may pass legalization next year, including Maryland, Pennsylvania, Florida and Ohio. With midterms in November, an economy still regaining its post-pandemic footing, and reform bills now coming from both sides of the aisle, the next few quarters could be a pivotal chapter in the story of North American cannabis. 

 

]]>
Source: One

Schaka

Related Posts

Flora Growth Enters Cannabis Beverage Market Through Licensing Agreement With Tonino Lamborghini

Unionized Budtender Gets Job Back

Palmitoylethanolamide: A Potential Alternative to Cannabidiol

Superlatives in news articles reporting non-FDA approved indications for use of cannabis and cannabis products with a focus on psychiatric disorders: a cross-sectional analysis

Signez la pétition !!!

 

846 signatures

Pétition ASBL Cannabis Belgique

Pourquoi une pétition ?

Nous sommes des personnes qui en avons assez de devoir aller dans la rue et avoir affaire à des réseaux criminels sans savoir où cela va nous conduire par après.

Nous sommes des personnes ayant des maladies, qui pour certaines sont rares, et utilisant pour médication le cannabis sous diverses formes (CBD,THC,THCv,CBDa,,,) sous l'accord de notre médecin.

Nous sommes des personnes responsables et honnêtes qui avons une vie épanouie et sans problèmes de vie ou sociaux.

Nous avons également une passion pour la plante de cannabis en elle-même et la cultiver est notre bonheur. De plus, nous pouvons nous soigner avec notre médication sans avoir peur des produits ou autres additifs contenus dans une plante que l'on peut trouver autre part.

Nous souhaitons pouvoir avoir notre médicament dans les normes de la santé publique, car un cannabis sain aide à réduire les frais de santé parfois conséquents pour la collectivité et le malade lui-même.

Nous sommes également des personnes responsables avec un rôle dans la société qui en avons assez d’être considérés comme des « hippies ou autres drogués », nous avons juste choisi notre médication et celle-ci a apporté les preuves de son efficacité dans le monde.

Nous connaissons déjà les produits dérivés comme le CBD et le THC que nous maîtrisons pour nous aider dans notre maladie « Je précise que nous ne sommes pas médecin et que nous nous basons sur 20 ans d’expérience médicale du cannabis des membres de notre ASBL et l'avis du médecin de famille ».

Nous désirons simplement ne plus nous cacher, et pouvoir aider les autres personnes le souhaitant.

Nous somme soucieux des ados et de la prévention à leur égard. Effectivement, nous sommes les acteurs parfaits pour répondre aux questions qu’ils se posent vu notre expérience cannabique et, de plus, nous pourrons leur expliquer les risques qu’ils encourent en achetant du cannabis dans la rue.

Le projet complet peut être demandé via mail " info@mcb.care " et sur le site internet : " http://mcb.care "

@ASBL McB

**votre signature**

Partagez avec vos amis

Articles récents

Catégories